Berenberg Bank Reaffirms Buy Rating for AstraZeneca (LON:AZN)

Berenberg Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research note released on Friday, Digital Look reports.

A number of other research analysts have also recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a hold rating and issued a £110 ($134.33) price objective on shares of AstraZeneca in a report on Tuesday, September 5th. Shore Capital reiterated a buy rating on shares of AstraZeneca in a research note on Wednesday, August 30th. Citigroup reiterated a buy rating on shares of AstraZeneca in a research note on Tuesday, July 18th. JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a research note on Monday, July 10th. Finally, UBS Group upgraded shares of AstraZeneca to a buy rating in a research note on Wednesday, July 12th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of £119.14 ($145.48).

Get AstraZeneca alerts:

Check Out Our Latest Stock Analysis on AZN

AstraZeneca Trading Up 1.3 %

AZN stock opened at £111.94 ($136.70) on Friday. The stock has a market cap of £173.51 billion, a price-to-earnings ratio of 3,520.13, a PEG ratio of 0.51 and a beta of 0.17. The business’s 50-day moving average is £107.97 and its 200 day moving average is £112.20. AstraZeneca has a 12-month low of GBX 9,499.21 ($116.00) and a 12-month high of £123.92 ($151.32). The company has a current ratio of 0.87, a quick ratio of 0.59 and a debt-to-equity ratio of 82.30.

AstraZeneca Cuts Dividend

The business also recently declared a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were issued a GBX 71.80 ($0.88) dividend. The ex-dividend date was Thursday, August 10th. This represents a dividend yield of 0.67%. AstraZeneca’s dividend payout ratio (DPR) is presently 7,389.94%.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

• Five stocks we like better than AstraZeneca
• Are Penny Stocks a Good Fit for Your Portfolio?
• 2 Must-Have Silicon Companies That Don’t Make Microchips
• Market Cap Calculator: How to Calculate Market Cap
• Small Caps That Have Priced In A Hard Landing For Big Upside
• How to Use High Beta Stocks to Maximize Your Investing Profits
• This May Have Ended Alibaba’s Winter, But Is It Time To Buy?

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.